A recently published study found that low vitamin D and K status is associated with a higher mortality risk.
Photo © iStockphoto.com/monkeybusinessimages
A recently published study found that low vitamin D and K status is associated with a higher mortality risk. The study included 4742 participants of the Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study with a mean age of 52 years, and a population that was 53% female. The PREVEND study is a prospective, observational cohort study in which subjects are screened every 3-4 years.
Results showed that in a 14-year follow-up, 620 participants had died, 142 of which died due to cardiovascular causes. Researchers observed that low vitamin D and K status was present in 970 participants (20%), and was associated with a greater risk of all-cause mortality compared to subjects with high vitamin D and K status. Similar, but non-significant trends were found for cardiovascular mortality and cardiovascular events. Interestingly, the combined association of low vitamin D and vitamin K status was greater than the sum of low vitamin D or K status alone. This indicates that the combined insufficiency amplifies mortality risk.
“To our knowledge, this is the first study to investigate the association of combined vitamin D and K status with mortality outcomes in the general population,” commented Trygve Bergeland, vice president, Science and Product Development at Kappa Bioscience, which manufactures the biologically active all-trans menaquinone-7 (vitamin K2 MK-7), marketed under the K2Vital brand name. “Proper nutrition is undeniably recognized as a crucial factor for good health. Vitamin D supplementation is common and certainly benefits bone health, with positive effects demonstrated on bone density and fracture prevention. Yet D needs to be balanced with K for proper cardiovascular health,” Bergeland continued. “Alone, it can increase calcium uptakes in the intestines but not activate MGP, which is responsible for inhibiting calcification in the vascular system.”
Cracking the code: Advancements in calcium absorption and nutritional understanding
July 23rd 2024Recent research conducted by ILSI U.S. and Canada – a global, nonprofit federation dedicated to advancing precompetitive research in the food, nutrition and health realms – and partially funded by Balchem, has shed light on how to improve predictions of Ca bioavailability across different food matrices.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.